Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Cancer medicine

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.
PMID: 29436178
Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13.

Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer...

PD-L1 Expression in Small Cell Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Yasuda Y, Ozasa H, Kim YH.
PMID: 29472058
J Thorac Oncol. 2018 Mar;13(3):e40-e41. doi: 10.1016/j.jtho.2017.10.013.

No abstract available.

Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Trends in biochemical sciences

Zhang J, Dang F, Ren J, Wei W.
PMID: 30287140
Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 01.

PD-L1, frequently expressed in human cancers, engages with PD-1 on immune cells and contributes to cancer immune evasion. As such, antibodies blocking the PD-1/PD-L1 interaction reactivate cytotoxic T cells to eradicate cancer cells. However, a majority of cancer patients...

Showing 1 to 3 of 3 entries